Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Antibody persistence and safety up to 12 months of heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose inactivated SARS-CoV-2 vaccine (CoronaVac) previously, has not been reported yet. This randomized, open-label, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Lairun, Tang, Rong, Wu, Shipo, Guo, Xiling, Huang, Haitao, Hou, Lihua, Chen, Xiaoqin, Zhu, Tao, Gou, Jinbo, Zhong, Jin, Pan, Hongxing, Cui, Lunbiao, Chen, Yin, Xia, Xin, Feng, Jialu, Wang, Xue, Zhao, Qi, Xu, XiaoYu, Li, Zhuopei, Zhang, Xiaoyin, Chen, Wei, Li, Jingxin, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519268/
https://www.ncbi.nlm.nih.gov/pubmed/36503413
http://dx.doi.org/10.1080/22221751.2022.2155251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519268/
https://www.ncbi.nlm.nih.gov/pubmed/36503413
http://dx.doi.org/10.1080/22221751.2022.2155251

Ejemplares similares